Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872358 | 0.88 | TSHR (0.48) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL11221440 | 0.88 | TSHR (0.48) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6802731 | 0.83 | IDO1 (0.44) | IDO1KMT2ACA1CA2CA9 | |
| SCHEMBL11448991 | 0.81 | TSHR (0.41) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6379469 | 0.81 | SLC1A3 (0.42) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14047282 | 0.81 | TSHR (0.41) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28576014 | 0.81 | SLC1A3 (0.42) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14754591 | 0.79 | ALDH1A1 (0.40) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27876875 | 0.78 | PSMB5 (0.41) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28230358 | 0.78 | PPARG (0.40) | TSHRIDO1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| EP-2751102-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| EP-2751102-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017165233-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017165233-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-5817776-A | TECHNETIUM 99 COMPLEXES, SINGLE PHOTON EMISSION TOMOGRAPHY | EMORY UNIVERSITY (US) | 1998-10-06 | — | — | US | disclosed |
| US-5808146-A | Amino acid analogs for tumor imaging | EMORY UNIVERSITY (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0862464-A1 | AMINO ACID ANALOGS FOR TUMOR IMAGING | EMORY UNIVERSITY (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997017092-A1 | AMINO ACID ANALOGS FOR TUMOR IMAGING | EMORY UNIVERSITY (US) | 1997-05-15 | — | — | WO | disclosed |
| EP-0352013-B1 | Hydroxymethyl cyclobutyl purines | SQUIBB & SONS INC (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0689460-A1 | CYCLOBUTYL ANTISENSE OLIGONUCLEOTIDES, METHODS OF MAKING AND USE THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| US-5369098-A | Viricides | E. R. SQUIBB & SONS, INC. (US) | 1994-11-29 | — | — | US | disclosed |
| US-5359044-A | Diagnosis, chemical intermediates | ISIS PHARMACEUTICALS (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994019023-A1 | CYCLOBUTYL ANTISENSE OLIGONUCLEOTIDES, METHODS OF MAKING AND USE THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0352013-A2 | Hydroxymethyl cyclobutyl purines | E.R. Squibb & Sons, Inc. (US) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HAVCR2, UGT2B7, GOT1 | TSHR 4496/4885IDO1 2568/4885SLC1A3 4113/4885 |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | PDE10A, PDE9A, PDE7A | TSHR 1522/4885IDO1 759/4885SLC1A3 3453/4885 |
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | HAVCR2, UGT2B7, GOT1 | TSHR 4496/4885IDO1 2568/4885SLC1A3 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.